NSE:ASTRAZEN

3 stories mentioning NSE:ASTRAZENUpdated 24d ago

Every FINWIRES story that references NSE:ASTRAZEN, newest first.

AstraZeneca Pharma India Gets India Approval to Use Enhertu in Breast Cancer Treatment

AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) has received permission from India's Central Drugs Standard Control Organization to import and distribute Enhertu (trastuzumab deruxtecan) for an additional breast cancer indication, according to a Thursday filing.The approval allows the drug, in combination with pertuzumab, to be used for first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, the filing said.AstraZeneca Pharma shares were down nearly 1% in after-market hours.

BOM:506820NSE:ASTRAZEN

Asia31d ago

Indian Equities End Marginally Higher on Thursday Ahead of Central Bank's Policy Decision

Indian benchmark indices finished marginally higher on Thursday after another range-bound session, as investors remained cautious ahead of the central bank's monetary policy announcement.The BSE Sensex rose 13.84 points, or 0.02%, to close at 74,360.01, while the NSE Nifty 50 gained 10.95 points, or 0.1%, to settle at 23,416.55.Trading remained subdued as market participants avoided aggressive positions ahead of the Reserve Bank of India's policy outcome. Weak global cues and elevated crude oil prices also kept sentiment in check.In corporate developments, HFCL (NSE:HFCL, BOM:500183) approved a series of transactions to consolidate its defense and aerospace operations under HFCL Advance Systems. The company plans to invest 892.5 million rupees in the newly formed unit as part of a broader 1.75 billion-rupee funding round and will retain a majority stake upon completion.AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) said its board approved the surrender of its factory license for cancellation, following previously announced plans to exit its manufacturing facility and relinquish its manufacturing license.

^BSENifty 50BOM:500183BOM:506820NSE:ASTRAZENNSE:HFCL

Asia31d ago

AstraZeneca Pharma India Gets Board Nod to Surrender Manufacturing License for Cancellation

AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) has received board approval to surrender its factory license to the Department of Factories, Boilers, Industrial Safety and Health, India, for cancellation, according to a Wednesday filing to the Indian stock exchanges.The license is valid from Dec. 14, 2023, to Dec. 31.The move follows the pharmaceutical company's earlier disclosures about exiting its manufacturing site and surrendering its manufacturing license.

BOM:506820NSE:ASTRAZEN

Track with the FINWIRES app suite

FolioX

Track NSE:ASTRAZEN in your portfolio

WheelAI

Analyze NSE:ASTRAZEN options with the wheel strategy

StockInsider

See market sentiment on NSE:ASTRAZEN